MedPath

Adult Congenital Heart Disease Registry (QuERI)

Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
Other: Observational
Registration Number
NCT01659411
Lead Sponsor
Actelion
Brief Summary

Multi-center, observational, U.S.-based longitudinal program. Data will be collected prospectively for 3 years. Individual physician feedback will be provided on data collected with the purpose of improving the management of patients - quality enhancement research initiative (QuERI) process from adult patients enrolled with a history of repaired Congenital Heart Disease (CHD).

Detailed Description

Approximately 800 male and female adult patients with a history of repaired CHD will be recruited from approximately 100 cardiology practices and will be followed up every twelve months for the period of three years. Consecutive patients in each practice meeting inclusion and exclusion criteria should be considered for the study. Two groups of subjects will be enrolled based on identical exclusion criteria and inclusion criteria, with the exception only of inclusion criteria #3: cohort 1- those demonstrating historic high risk criteria and cohort 2 - those demonstrating current high risk criteria.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
217
Inclusion Criteria

Cohort 1 (historic high risk)

  1. Male and female adults (≥ 18 years of age)

  2. Patients with documented history (at least one year) of an isolated, repaired congenital heart defect such as ASD, VSD, PDA, AVC (AVSD)

  3. History of a large defect prior to closure as evidenced by any one of the following:

    • Size of: ASD > 2 cm; VSD > 1 cm; PDA > 0.6 cm
    • Shunt 2:1 or greater
    • Pre-operative PH (PAS > 40 mmHg) or documented shunt- related heart failure (radiographic evidence)
    • Pre-operative atrial fibrillation or flutter
  4. High risk features (any one the following):

    • Age > 40 years

    • Later surgical repair:

      i. ≥ 2 years of age for PDA or VSD ii. ≥ 1 year of age for AVC iii. ≥ 10 years of age for ASD

    • Sinus venosus defect

    • Primum defect

    • WHO functional class > 1

    • Atrial fibrillation or flutter

  5. Echocardiographic evidence of high risk features. Any one of the following:

    • Degree of TR that is mild or greater

    • Right ventricular (RV) systolic dysfunction

    • Evidence of RV dilatation: Any one of the following:

      i. Evidence of RV dilation by general, qualitative assessment ii. RV end diastolic diameter > 3.2 cm on apical 4 chamber view at the tips of the tricuspid valve iii. RV to LV ratio at end-diastole > 0.6 (RV and LV end diastolic dimensions measured from apical 4 chamber view, 1 cm apical of the respective valve annuli)

    • Any abnormality in the motion of the inter-ventricular septum

  6. Ability and desire to execute the consent for follow up

Inclusion Criteria: Cohort 2 (current high risk)

  1. Male and female adults (≥ 18 years of age)

  2. Patients with documented history (at least one year) of an isolated, repaired congenital heart defect such as ASD, VSD, PDA, AVC (AVSD)

  3. Current (within the last 12 months) evidence of 1 or more of the 7 following criteria:

    • Desaturation on exercise (92% or less)
    • 6 MWD <380 m
    • PFT demonstrating DLC <70% predicted & FEV1>70% predicted
    • ECG demonstrating i) RAD and ii) RVH or RAE
    • Physical findings of edema accompanied by elevated JVP and +HJR
    • CXR evidence of enlarged main and/or hilar pulmonary arterial shadows in association with right ventricular enlargement
    • Elevated biomarks (BNP or NT-proBNP above upper limit of normal)
  4. High risk features (any one of the following:)

    • Age > 40 years

    • Later surgical repair:

      i. ≥ 2 years of age for PDA or VSD ii. ≥ 1 year of age for AVC iii. ≥ 10 years of age for ASD

    • Sinus venosus defect

    • Primum defect

    • WHO functional class > 1

    • Atrial fibrillation or flutter

  5. Echocardiographic evidence of high risk features. Any one of the following:

    • Degree of TR that is mild or greater

    • Right ventricular (RV) systolic dysfunction

    • Evidence of RV dilatation: Any one of the following:

      i. Evidence of RV dilation by general, qualitative assessment ii. RV end diastolic diameter > 3.2 cm on apical 4 chamber view at the tips of the tricuspid valve iii. RV to LV ratio at end-diastole > 0.6 (RV and LV end diastolic dimensions measured from apical 4 chamber view, 1 cm apical of the respective valve annuli)

    • Any abnormality in the motion of the inter-ventricular septum

  6. Ability and desire to execute the consent for follow up

Exclusion Criteria
  1. Poor mental function, drug or substance (e.g., alcohol) abuse, or unstable psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study
  2. Diagnosis of PAH (defined as RHC demonstrating mPAP ≥ 25 mm Hg and PCWP ≤ 15 and PVR > 3 WU or PVR (indexed) > 4 WU or treatment with PAH specific therapy) after surgical repair and prior to visit 1
  3. Prior inclusion in this registry

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Adult CHD PatientsObservationalobservational
Primary Outcome Measures
NameTimeMethod
To characterize the clinical course in a cohort of adult patients with repaired CHD at risk for developing PAHscreening (visit 1) through end of study (3 years)

outcome measure: clinical outcomes: Assessment of function status, medications, and laboratory results, as well as an evaluation of medical history, physical examination, ECG, and echocardiography, in adult congenital heart disease patients at risk for pulmonary hypertension.

Secondary Outcome Measures
NameTimeMethod
To characterize the clinical outcomes in a cohort of adult patients with repaired CHD at risk for developing PAHscreening (visit 1) through end of study (3 years)

outcome measure: clinical rate: To assess the rate of newly diagnosed pulmonary arterial hypertension in a cohort of adults with repaired congenital heart disease at risk for pulmonary arterial hypertension. To also compare clinical outcomes in patients who do and do not meet prespecified echocardiography criteria for suspected pulmonary arterial hypertension.

Trial Locations

Locations (59)

Temple University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

University of Chicago

🇺🇸

Chicago, Illinois, United States

Texas Children's Hospital/Baylor College of Medicine

🇺🇸

Houston, Texas, United States

Barnes-Jewish Hospital/Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

The Research Institute at Nationwide Children's Hospital

🇺🇸

Columbus, Ohio, United States

Montefiore Medical Center - Moses Division;The University Hospital for Albert Einstein College of Medicine

🇺🇸

Bronx, New York, United States

The Pennsylvania State University College of Medicine and The Pennsylvania State Milton S. Herhsey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Berkeley Cardiovascular Medical Group

🇺🇸

Oakland, California, United States

University of Southern California ACHD Care Program

🇺🇸

Los Angeles, California, United States

Children's Hospital Boston and Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

Children's National Medical Center and Washington Hospital Center

🇺🇸

Washington, District of Columbia, United States

Capital District Pediatric Cardiology Associates

🇺🇸

Albany, New York, United States

Center for Adults with Congenital Heart Disease

🇺🇸

Boston, Massachusetts, United States

The Cleveland Clinic Adult Congenital Heart Disease Center

🇺🇸

Cleveland, Ohio, United States

Bay Area Cardiology Assoc., P.A.

🇺🇸

Brandon, Florida, United States

Memorial Regional Hospital

🇺🇸

Hollywood, Florida, United States

Advocate Medical Group

🇺🇸

Oak Lawn, Illinois, United States

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

University of Virginia Health Systems

🇺🇸

Charlottesville, Virginia, United States

Children's Specialty Group PLLC, Children's Hospital of the King's Daughters

🇺🇸

Norfolk, Virginia, United States

University of Maryland

🇺🇸

Baltimore, Maryland, United States

Hospital of University of Pennsylvania; Childrens Hospital of Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

Cohen's Children's Medical Center of New York

🇺🇸

New Hyde Park, New York, United States

Methodist Lebonheur Healthcare, UT Lebonheur Pediatric Specialists

🇺🇸

Memphis, Tennessee, United States

The Cardiovascular Group Central

🇺🇸

Lynchburg, Virginia, United States

The Queen's Heart Physician Practice

🇺🇸

Honolulu, Hawaii, United States

The University of Kansas Hospital

🇺🇸

Kansas City, Kansas, United States

University of California, San Francisco

🇺🇸

San Francisco, California, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

Phoenix Children's Hospital, Children's Heart Center

🇺🇸

Phoenix, Arizona, United States

University of Colorado Hospital

🇺🇸

Aurora, Colorado, United States

Childrens Heart Center Nevada

🇺🇸

Las Vegas, Nevada, United States

University of Minnesota Physicians Heart Fairview

🇺🇸

Minneapolis, Minnesota, United States

Cincinnati Adolescent and Adult Congenital Heart Disease Program, The Heart Institute at Cincinnati Childrens Hospital Medical Center

🇺🇸

Cincinnati, Ohio, United States

University of Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

Oregon Health and Science Univ.

🇺🇸

Portland, Oregon, United States

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

Ohio State University Medical Center

🇺🇸

Columbus, Ohio, United States

Central Bucks Specialists

🇺🇸

Doylestown, Pennsylvania, United States

East Carolina Heart Institute of East Carolina University

🇺🇸

Greenville, North Carolina, United States

Ahmanson / UCLA Adult Congenital Heart Disease Center

🇺🇸

Los Angeles, California, United States

Bassett Healthcare Network - Bassett Medical Center

🇺🇸

Cooperstown, New York, United States

Mount Sinai Pulmonary Hypertension Program

🇺🇸

New York, New York, United States

Schneeweiss Adult Congenital Heart Center - Columbia University Medical Center

🇺🇸

New York, New York, United States

Pulmonary Health Physicians, PC

🇺🇸

Syracuse, New York, United States

Lenox Hill Heart and Vascular Institute-LIJ North Shore

🇺🇸

New York, New York, United States

Asheville Cardiology Associates

🇺🇸

Asheville, North Carolina, United States

Lucile Packard Children's Hospital

🇺🇸

Palo Alto, California, United States

Yale School of Medicine - Adult Congenital Heart Disease Program

🇺🇸

New Haven, Connecticut, United States

University of Louisville, Pediatric Cardiology

🇺🇸

Louisville, Kentucky, United States

University of Michigan Adult Congenital Program

🇺🇸

Ann Arbor, Michigan, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Mid-America Heart Institute / St Luke's Hospital / Saint Luke's Cardiovascular Consultants

🇺🇸

Kansas City, Missouri, United States

Connecticut Children's Medical Center

🇺🇸

Hartford, Connecticut, United States

The University of Arkansas for Medical Sciences - Arkansas Children's Hospital

🇺🇸

Little Rock, Arkansas, United States

Pediatric Cardiology Associates

🇺🇸

Portland, Maine, United States

University of Washington

🇺🇸

Seattle, Washington, United States

West Virginia University Department of Pediatrics

🇺🇸

Morgantown, West Virginia, United States

University of Florida, Shands Hospital

🇺🇸

Gainesville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath